Asia-based Financial Group Launches $50M US Biotech Fund

Mirae Asset Capital Life Science: A New Player in Biotech with $50M Funding

Mirae Asset Capital Life Science has recently emerged from stealth mode with a significant $50 million fund dedicated to supporting U.S. biotech companies. The venture capital firm, which is the only U.S. arm of the Mirae Asset Financial Group headquartered in Seoul, South Korea, aims to provide funding to promising private biotechs. With a presence in Boston and San Francisco, the firm is ready to invest in biotech companies at various stages of development.